Klacid Saft

Clarithromycin, the active ingredient in Klacid Saft, is a macrolide antibiotic presented as an oral solution for oral administration. It is used to treat a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, skin and soft‑tissue infections, Helicobacter pylori eradication regimens, and streptococcal pharyngitis in adults and children.

GNH USA supplies Klacid Saft as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for qualified healthcare providers with consistent quality and regulatory compliance.

Clarithromycin is a macrolide antibiotic that targets bacterial infections of the respiratory and skin systems. - Community‑acquired pneumonia: effective in eliminating the causative bacteria and improving respiratory symptoms. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Skin and soft‑tissue infections: treats cellulitis, impetigo and other bacterial skin conditions. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple‑therapy regimens. - Streptococcal pharyngitis: alleviates throat infection and prevents complications.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may be watery. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate headache episodes. - Vomiting: occasional episodes of emesis.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty. - QT interval prolongation: potential cardiac arrhythmia risk. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing clarithromycin, consider the following precautions to ensure safe use. - Assess renal function: dose adjustment may be needed in impaired kidney function. - Monitor liver enzymes: hepatic impairment can increase drug exposure. - Avoid in patients with known QT prolongation: risk of cardiac arrhythmias. - Use with caution in pregnancy: safety category is unknown, weigh benefits versus risks. - Review concomitant medications: potential for drug‑drug interactions. - Store at room temperature: keep in the original container, protect from moisture and light.

Clarithromycin interacts with several medicines; categorize them by clinical significance.

Major Interactions (Avoid): - Cisapride: co‑administration can cause serious QT prolongation. - Pimozide: risk of life‑threatening arrhythmias when combined. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may lead to toxic clarithromycin levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce clarithromycin efficacy. - Warfarin: may increase INR and bleeding risk. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously. - Oral contraceptives: possible reduction in contraceptive effectiveness.